Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder

The mechanism by which bacillus Calmette-Guérin (BCG) mediates antitumor activity has not been clearly established. Specific cytokines in the urine after BCG intravesical instillation therapy may serve as a prognostic factor of treatment response. In this study, various urinary cytokines such as int...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2003-08, Vol.52 (8), p.481-486
Main Authors: WATANABE, Etsuya, MATSUYAMA, Hideyasu, MATSUDA, Kenji, OHMI, Chietaka, TEI, Yasuhide, YOSHIHIRO, Satoru, OHMOTO, Yasukazu, NAITO, Katsusuke
Format: Article
Language:English
Subjects:
Administration, Intravesical
Aged
Aged, 80 and over
Antineoplastic agents
BCG Vaccine - administration & dosage
BCG Vaccine - therapeutic use
Biological and medical sciences
Biomarkers, Tumor - urine
Carcinoma in Situ - drug therapy
Carcinoma in Situ - urine
Case-Control Studies
Cytokines - urine
Female
Humans
Immunotherapy
Interleukin-2 - urine
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - therapy
Neoplasm Recurrence, Local - urine
Neoplasm Staging
Original
Pharmacology. Drug treatments
Prognosis
Tumor Necrosis Factor-alpha - urine
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - urine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mechanism by which bacillus Calmette-Guérin (BCG) mediates antitumor activity has not been clearly established. Specific cytokines in the urine after BCG intravesical instillation therapy may serve as a prognostic factor of treatment response. In this study, various urinary cytokines such as interleukin-1beta (IL-1beta), IL-2, IL-6, IL-8. IL-10, IL-12, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) were measured. In total 20 patients were treated with BCG intravesical instillation therapy for carcinoma in situ of the bladder. At the completion of the first and eighth instillations, spontaneously voided urine specimens were collected before BCG instillation, every 2 h until 12 h, and thereafter until 24 h. All specimens were ultrafiltrated using an ADVANTEC UK-10 membrane. The cytokines were measured using ELISA and RIA techniques. Significantly higher levels of IL-2, IL-6, IL-8, IL-10, IFN-gamma, and TNF-alpha were detected in the eighth instillation as compared to the first instillation ( p
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-003-0384-9